Hemodynamic effects of albumin dialysis in patients with liver failure: For better or for worse?

Therapeutic Apheresis and Dialysis

Volumn 13, Issue 5, 2009, Pages 384-392

  Laleman, Wim ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Hyperdynamic circulation; Liver failure; Molecular adsorbent recirculating system; Portal hypertension; Prometheus

Indexed keywords

ALBUMIN; AMMONIA; AROMATIC AMINO ACID; DISULFIRAM; DOBUTAMINE; INTERLEUKIN 6; ISONIAZID; NITRIC OXIDE; NORADRENALIN; PARACETAMOL; PROSTANOID; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; VASOPRESSIN;

ALBUMIN DIALYSIS; ARTIFICIAL LIVER; BINDING AFFINITY; DRUG OVERDOSE; HEMODYNAMIC PARAMETERS; HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS NON A NON B; HEPATORENAL SYNDROME; HUMAN; LIVER FAILURE; LIVER ISCHEMIA; LIVER TOXICITY; MEAN ARTERIAL PRESSURE; MOLECULAR MECHANICS; MULTIPLE ORGAN FAILURE; OXIDATIVE STRESS; PATHOGENESIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ALBUMINS; DIALYSIS; HEMODYNAMICS; HUMANS; LIVER FAILURE; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70349787233     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00756.x     Document Type: Review

References (47)

1. Laleman W, Wilmer A, Evenepoel P et al. Non-biological liver support in liver failure. Aliment Pharmacol Ther 2006 23 : 351 363.
2. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002 22 (Suppl. 2 5 13.
3. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 2002 20 : 252 261.
4. Stadlbauer V, Davies NA, Sen S et al. Artificial liver support systems in the management of complications of cirrhosis. Semin Liver Dis 2008 28 : 96 109.
5. Larsen FS, Hansen BA, Blei AT. Intensive care management of patients with acute liver failure with emphasis on systemic hemodynamic instability and cerebral edema: a critical appraisal of pathophysiology. Can J Gastroenterol 2000 14 (Suppl. D D105 111.
6. Laleman W, Van Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int 2005 25 : 1079 1090.
7. Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 2007 132 : 709 719.
8. Williams R. The elusive goal of liver support - quest for the Holy Grail. Clin Med 2006 6 : 482 487.
9. Llach J, Gines P, Arroyo V et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988 94 : 482 487.
10. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001 34 : 46 52.
11. Evenepoel P, Laleman W, Wilmer A et al. Detoxifying capacity and kinetics of prometheus - a new extracorporeal system for the treatment of liver failure. Blood Purif 2005 23 : 349 358.
12. Evenepoel P, Laleman W, Wilmer A et al. Prometheus versus MARS: comparison of efficiency in two different liver detoxification devices. Artif Organs 2006 30 : 276 284.
13. Stange J, Mitzner SR, Risler T et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999 23 : 319 330.
14. Rifai K, Ernst T, Kretschmer U et al. Prometheus - a new extracorporeal system for the treatment of liver failure. J Hepatol 2003 39 : 984 990.
15. Arroyo V. Review article: albumin in the treatment of liver diseases - new features of a classical treatment. Aliment Pharmacol Ther 2002 16 (Suppl. 5 1 5.
16. Kowalski HJ, Abelman WH. The cardiac output at rest in Laennecs cirrhosis. J Clin Invest 1953 32 : 1025.
17. Trewby PN, Williams R. Pathophysiology of hypotension in patients with fulminant hepatic failure. Gut 1977 18 : 1021 1026. (Pubitemid 8263411)
18. Trewby PN, Hanid MA, MacKenzie RL, Mellon PJ, Williams R. Effects of cerebral oedema an arterial hypotension on cerebral blood flow in an animal model of hepatic failure. Gut 1978 19 : 999 1005.
19. Bihari DJ, Gimson AE, Williams R. Cardiovascular, pulmonary and renal complications of fulminant hepatic failure. Semin Liver Dis 1986 6 : 119 128.
20. Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver diseases. In : Bosch J, Groszmann RJ, eds. Portal hypertension: Pathophysiology and Treatment. Oxford : Blackwell Science, 1994 17 26.
21. Wiest R, Das S, Cadelina G. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999 104 : 1223 1233.
22. Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharm Therap 2001 89 : 221 231.
23. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000 32 (Suppl. 1 141 156.
24. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Light and shadows in an important clinical problem. J Hepatol 2000 32 (Suppl. 1 157 170.
25. Tsai MH, Chen YC, Lien JM et al. Hemodynamics and metabolic studies on septic shock in patients with acute liver failure. J Crit Care 2008 23 : 468 472.
26. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003 9 : 290 297.
27. Tsai MH, Chen YC, Wu CS et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with hepatitis B-associated fulminant hepatic failure. Int J Clin Pract 2005 59 : 1289 1294.
28. Lai WK, Haydon G, Mutimer D, Murphy N. The effect of molecular adsorbent recirculating system on pathophysiological parameters in patients with acute liver failure. Intensive Care Med 2005 31 : 1544 1549.
29. Novelli G, Rossi M, Poli L et al. Primary non-function: timing retransplantation versus hemodynamic parameters and kidney function. Transplant Proc 2008 40 : 1854 1857.
30. Mitzner SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000 6 : 277 286.
31. Schmidt LE, Sorensen VR, Svendsen LB, Hansen BA, Larsen FS. Hemodynamic changes during a single treatment with the molecular adsorbent recirculating system in patients with acute-on-chronic liver failure. Liver Transpl 2001 7 : 1034 1039.
32. Sorkine P, Ben Abraham R, Szold O et al. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 2001 29 : 1332 1336. (Pubitemid 32641793)
33. Heemann U, Treichel U, Loock J et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002 36 : 949 958.
34. Catalina MV, Barrio J, Anaya F et al. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int 2003 23 (Suppl. 3 39 43.
35. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003 38 : 24 31.
36. Sen S, Davies NA, Mookerjee RP et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004 10 : 1109 1119.
37. Sen S, Mookerjee RP, Cheshire LM, Davies NA, Williams R, Jalan R. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 2005 43 : 142 148.
38. Laleman W, Wilmer A, Evenepoel P et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006 10 : R108.
39. Dethloff T, Tofteng F, Frederiksen HJ, Hojskov M, Hansen BA, Larsen FS. Effect of Prometheus liver assist system on systemic hemodynamics in patients with cirrhosis: a randomized controlled study. World J Gastroenterol 2008 14 : 2065 2071.
40. Stadlbauer V, Krisper P, Aigner R et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 2006 10 : R169.
41. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002 35 : 478 491.
42. Griffith TM. Role of nitric oxide in the regulation of blood flow. In : Ignarro LJ, ed. Nitric Oxide: Biology and Pathobiology. London : Academic Press, 2000 483 502.
43. Stamler JS, Simon DI, Jaraki O et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992 89 : 7674 7677.
44. Rafikova O, Rafikov R, Nudler E. Catalysis of S-nitrosothiols formation by serum albumin: the mechanism and implication in vascular control. Proc Natl Acad Sci U S A 2002 99 : 5913 5918.
45. Guo LM, Liu JY, Xu DZ et al. Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int 2003 23 (Suppl. 3 16 20.
46. Klammt S, Mitzner SR, Stange J et al. Improvement of impaired albumin binding capacity in acute-on-chronic liver failure by albumin dialysis. Liver Transpl 2008 14 : 1333 1339.
47. Oettl K, Stadlbauer V, Petter F et al. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta. 2008 1782 : 469 473.